CERUMENEX
LOE ApproachingPeptidetrolamine polypeptide oleate condensate
NDAOTICSOLUTION/DROPS
Approved
Jun 1958
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 5d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CERUMENEX (trolamine polypeptide oleate condensate) is an otic solution approved in 1958 for cerumen impaction removal. It works as a cerumenolytic agent that softens and facilitates the mechanical removal of earwax. The drug addresses a common ENT condition affecting patients with excessive or impacted cerumen buildup.
LOE Approaching
Legacy product with approaching loss of exclusivity and minimal linked career opportunities; team structure likely focused on maintenance rather than growth.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
CERUMENEX offers minimal career growth due to zero linked job openings and approaching loss of exclusivity. Roles on this product typically involve maintenance and compliance rather than strategic innovation or team expansion.
Brand ManagerField Sales Representative
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.